JP Morgan lifts 3M target to $210 as the stock outpaces industrial peers

MMM closed at $177.05 on Tuesday, up 3.2% over the past week, against a median decline of roughly 0.3% for its closest correlated peers. The standout this week is not short interest, which remains negligible, but analyst conviction: JP Morgan raised its price target to $210 on Wednesday, the highest published target in the recent changes register, while the stock continues to build on a strong Q3 earnings reaction.

The analyst picture has shifted materially since October 21, when 3M reported quarterly results. That morning, JP Morgan lifted its target from $185 to $191 while keeping its Overweight rating. Citigroup and Bernstein both raised targets in the same session, to $188 and $197 respectively, though neither moved off their cautious ratings. The lone dissenter was RBC Capital, which nudged its Underperform target only marginally higher to $135. Then on November 4, JP Morgan went further, pushing its target to $210, now 19% above Wednesday's close of $177.05. The bull case centres on margin expansion, with 3M targeting a further 100 basis points of segment-level operating margin growth in 2026 on top of the 24.4% adjusted operating margin reported in Q3 2025. The bear case is more structural: a soft Consumer segment, decelerating Chinese industrial output, and unresolved PFAS litigation risk. At current levels, the stock trades on a trailing P/E of 18.1, up roughly 1.1 turns over the past 30 days, and EV/EBITDA of 12.1, which has compressed by 0.3 turns over the same period. The EPS surprise factor score ranks in the 76th percentile, and the 12-month forward EPS growth score is at the 79th percentile, suggesting the Street's upward revisions have continued momentum behind them.

Short interest carries no meaningful story here. Bears hold just 1.8% of the free float short, down about 1.7% over the past week, and the borrow market is fully unconstrained: availability is at the ceiling, with more than 515 million shares available to lend against roughly 9.7 million shares currently borrowed. Cost to borrow is 0.58% annually, the highest in roughly six weeks, but still well inside the range where it matters. The options market tells a similarly relaxed story. The put/call ratio is 0.61, slightly below its 20-day average of 0.64 and about 1.2 standard deviations on the call-heavy side. That is not aggressive positioning in either direction. The ORTEX short score of 32.2 is in the 51st percentile and has been flat for two weeks.

The buyback announcement on November 3, a $6 billion authorization, is worth placing in context here. As reported in prior ORTEX notes, ORTEX Alt Data records Q2 2026 as the largest quarter for 3M buyback spend in seven years, at $994 million. The new authorization confirms management is willing to continue allocating capital to repurchases at that scale, though no shares have yet been purchased under the new program. With retail attention running elevated, an ORTEX Wikipedia views z-score of 2.2 against 3M's own trailing 90-day history as of October 21, the authorization landed in front of an audience paying closer attention than usual.

The Q3 earnings print on October 20 produced a 7.9% one-day gain, the strongest single-day earnings reaction in the recent history register. The five-day follow-through was 5.9%. The prior print, from late October 2026 (a duplicate record in the data), showed a negligible one-day move of minus 0.7%, suggesting reaction size varies considerably. JP Morgan's upgraded target to $210 and the Q4 earnings date of January 20, 2027 are the two specific markers to watch: how far target upgrades extend beyond JP Morgan's $210, and whether the Q4 print can sustain the kind of reaction October's results generated.